1. Home
  2. COCO vs MLYS Comparison

COCO vs MLYS Comparison

Compare COCO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Vita Coco Company Inc.

COCO

The Vita Coco Company Inc.

HOLD

Current Price

$53.77

Market Cap

3.0B

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$24.47

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COCO
MLYS
Founded
2004
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.4B
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
COCO
MLYS
Price
$53.77
$24.47
Analyst Decision
Buy
Strong Buy
Analyst Count
9
6
Target Price
$58.13
$48.67
AVG Volume (30 Days)
1.1M
1.1M
Earning Date
04-29-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
26.60
37.43
EPS
1.19
N/A
Revenue
N/A
N/A
Revenue This Year
$16.12
N/A
Revenue Next Year
$11.40
N/A
P/E Ratio
$46.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.79
$10.44
52 Week High
$61.39
$47.65

Technical Indicators

Market Signals
Indicator
COCO
MLYS
Relative Strength Index (RSI) 46.20 39.48
Support Level $50.40 $13.42
Resistance Level $55.43 $31.09
Average True Range (ATR) 2.49 1.62
MACD -0.31 -0.15
Stochastic Oscillator 32.98 24.24

Price Performance

Historical Comparison
COCO
MLYS

About COCO The Vita Coco Company Inc.

The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: